Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Phase 3 Completed 392 enrolled Zydus Lifesciences Limited

RandomizedParallel-groupOpen-labelTreatment

Summary

A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)

Timeline

Start: 2020-01-04
Primary completion: 2021-09-02
Completion: 2021-09-02

Publications

Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Desidustat	Small molecule	100 mg	Oral
Subject	epoetin alfa	Protein / enzyme biologic	—	Other

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Summary

Timeline

Publications

Drugs

Indications